Skip to main content

and
  1. Article

    Open Access

    STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

    Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance...

    Marjolaine Debant, Miguel Burgos, Patrice Hemon in Journal for ImmunoTherapy of Cancer (2019)

  2. Article

    Open Access

    17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when...

    Cristina Bagacean, Adrian Tempescul, David Ternant in Journal for ImmunoTherapy of Cancer (2019)